DNA拓扑异构酶Ⅰ在骨肉瘤中的表达及临床意义

Expression and clinical significane of DNA Topoisomerasc I in osteosarcoma

目的 研究骨肉瘤中TopoⅠ的表达情况,探讨其与TopoⅡ、Ki67之间的相互关系和临床意义。方法 采用S-P免疫组化方法,检测TopoⅠ、TopoⅡ和Ki67在67例骨肉瘤、10例骨样骨瘤、15骨软骨瘤及15例正常骨组织中的表达,分析相互间的关系,对其中31例随访资料进行生存分析。结果 67例骨肉瘤中,TopoⅠ、TopoⅡ与和Ki67的表达率分别为22.39％、44.78％和40.30％,均明显增高,同患者术后生存率呈负相关;TopoⅠ、TopoⅡ的表达率与应用于临床的抗DNA拓扑异构酶化疗药物有效率相近。结论骨肉瘤中有小部分患者对于新的以TopoⅠ为靶点的化疗药物敏感,对骨肉瘤组织行免疫组化方法检测TopoⅠ、TopoⅡ可能作为骨肉瘤患者选择化疗方案一个较为简单又有意义的指标。

Objective To investigate the expression of Topo Ⅰ, Topo Ⅱ and Ki67 in osteosarcoma and the corre- lation between among them and their clinical significance. Methods The expression of Topo Ⅰ,Topo Ⅱ and Ki67 in 67 osteosarcoma, 15 exostosis, 10 osteoid osteoma and 15 normal bone tissues were studied by SP immunoperoxidase meth- ods. The correlation among them were analyzed; Follow-up data from 31 patiants were analyzed to obtain survival fig- ures. Results The positive expression rates of Top Ⅰ,Topo Ⅱ and Ki67 in 67 cases with osteosarcoma were 22.39%, 44.78%,40.30% respectively. These expression rates were significant hinger than those in other groups and negative correlation was seen between these expression rates and the prognosis of patients with osteosarcoma. The expression rates of Topo Ⅰ and Topo Ⅱ were similar to the percentage of patients that responded to topoisomersase-targeted drugs in clini- cal trials. Conclusions Our data suggest that the new drugs targeting Topo Ⅰ might be well-responded in the small part of osteosarcoma. Immunostains for both Topo Ⅰ, Topo Ⅱ might be a simpie and sensitive index to select chemotherapy regime in patients with osteosarcoma. It may be possible to test this hypothesis in a large clinical trial.